Form 4 for RGNX REGENXBIO Inc.
Accepted 2026-07-01 20:08:30 ET · period of report 2026-06-29 · accession 0001700659-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-07-01 20:08 | 2026-06-29+ | RGNX | PAKOLA STEVE | Chief Medical Off | S - Sale+OE | $12.23 | -56.3K | 213.0K | -21% | -$688.8K |
| D | 2026-07-01 20:08 | 2026-07-01 | RGNX | PAKOLA STEVE | Chief Medical Off | M - OptEx | $7.86 | +36.7K | 249.7K | +17% | +$288.7K |
| D | 2026-07-01 20:08 | 2026-07-01 | RGNX | PAKOLA STEVE | Chief Medical Off | M - OptEx | $0.00 | -36.7K | 67.0K | -35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | S | D | 19,608 | $11.04 | 213,009 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan. (F2) This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2026-07-01 | M | A | 36,725 | $7.86 | 249,734 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 36,725 | $12.86 | 213,009 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
| 4 | Derivative | Stock Options (Right to Buy) | 2026-07-01 | M | D | 36,725 | $0.00 | 66,973 | D | $7.86 · — to 2035-01-02 | 36,725 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan. (F3) The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer |